Skip to main content
main-content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Musculoskeletal Disorders 1/2015

Rivaroxaban does not impair fracture healing in a rat femur fracture model: an experimental study

Zeitschrift:
BMC Musculoskeletal Disorders > Ausgabe 1/2015
Autoren:
Tim Klüter, Matthias Weuster, Stefan Brüggemann, Leif Menzdorf, Stefanie Fitschen- Oestern, Nadine Steubesand, Yahya Acil, Thomas Pufe, Deike Varoga, Andreas Seekamp, Sebastian Lippross
Wichtige Hinweise
Tim Klüter and Matthias Weuster contributed equally to this work.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

TK drafted the manuscript, participated in its design and performed the statistical analysis. MW carried out the surgical procedures and participated in its design and coordination. SB carried out the surgical procedures and the biomechanical testing and performed the statistical analysis. LM carried out the surgical procedures and carried out the biomechanical testing. SF conceived of the study and carried out the histologic assessment. NS carried out the histologic staining and participated in its design and coordination. YA carried out the histologic staining. TP participated in the design of the study and performed the statistical analysis. DV participated in the biomechanical testing. AS conceived of the study and participated in its design. SL designed the study, participated in its coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Abstract

Background

The prescription of the oral anticoagulant rivaroxaban to prevent thromboembolic episodes associated with orthopaedic surgery has dramatically increased since it was introduced. Rivaroxaban is beeing prescribed although recent in-vitro studies revealed that it impaired osteoblast metabolism. In this study we analysed the effect of rivaroxaban on fracture healing in a rat femur fracture model.

Methods

Femur fractures were created by a 3-point-bending device in 48 Wistar rats and subsequently stabilized by intramedullary nailing. After the surgical procedure animals were randomised into four groups. Two groups were fed with 3 mg rivaroxaban per kg body weight per day and two control groups were fed with chow only. Animals were euthanized 28 or 49 days after surgical procedure. Femurs underwent undecalcified histologic staining micro CT scanning and biomechanical testing. The statistical significance was evaluated using one-way Anova with Bonferroni correction.

Results

Micro CT-scans revealed significantly increased volume of bone tissue in the fracture zone between day 28 and 49. During the same time callus volume decreased significantly. Comparing the fracture zone of the rivaroxaban group to the control group the treated group revealed a larger callus and a marginal increase of the tissue mineral density. The torsional rigidity was not influenced by the treatment of rivaroxaban.

Conclusion

In the present study we were able to demonstrate that rivaroxaban does not impair fracture healing in a rat femur fracture model. Considering the fact that low molecular weight heparins delay fracture healing significantly, rivaroxaban might be an improved alternative.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Musculoskeletal Disorders 1/2015 Zur Ausgabe

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Orthopädie und Unfallchirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise